New @ NATAP
Reported by Jules Levin
ACG Annual Scientific Meeting
Philadelphia, PA, October 20, 2014
Abbvie 3D at ACG
ACG: MANAGEMENT OF HEMOGLOBIN DECREASE IN PATIENTS TREATED WITH ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE-1 INFECTED PATIENTS - (10/20/14)
ACG: NORMALIZATION OF LIVER-RELATED LABORATORY PARAMETERS IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS AFTER TREATMENT WITH ABT-450/R/OMBITASVIR, DASABUVIR AND RIBAVIRIN - (10/20/14)
ACG: Sustained Virologic Response 12 Weeks Post-treatment With ABT-450/Ritonavir/Ombitasvir and Dasabuvir With Ribavirin (SAPPHIRE I and II) Is Independent of Patient Subgroups - (10/20/14)
ACG: Low Incidence of Hyperbilirubinaemia With Ombitasvir-ABT-450/r and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients - (10/20/14)
ACG: Results From the Phase 2 PEARL-I Study: Interferon-free Regimens of ABT-450/r + ABT-267 With or Without Ribavirin in Patients With HCV Genotype 4 Infection - (10/20/14)
ACG: Safety Comparison of 12- and 24-Week Treatments in HCV Genotype 1-Infected Patients With Cirrhosis: Results From TURQUOISE-II - (10/20/14)
Additional Coverage @
ACG Annual Scientific Meeting
No comments:
Post a Comment